英矽智能发布了ISM001-055药物临床试验结果。该药物由生成式人工智能设计，旨在治疗慢性肺病特发性肺纤维化（IPF）。美国约有10万IPF患者，随着病情发展，患者呼吸会愈发困难。

全球与中国司库奇尤单抗注射液市场运营态势及前景预测研究报告2024-2030年 【内容部分有删减·详细可参中智信投研究网出版完整信息！】 2.1 全球司库奇尤单抗注射液总体市场规模：2023 VS 2030 ...

Novartis has a long way to go to make its twice-yearly cholesterol-lowering drug Leqvio the multi-billion-dollar blockbuster it is predicting – but took another step along that road today.

数据表明， 早在治疗14天时即可观察到Fabhalta可减少C3G患者的蛋白尿，此结果具临床意义并持续至12个月。 在研究的开放标签阶段，切换至Fabhalta的受试者也表现出蛋白尿的减少。

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...

As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss pharma’s top-selling drug Entresto. In a court decision filed this ...

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines ...

Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. The deal, which features $1.1 billion in milestones, covers the global rights to a small ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali ...

No significant news for NVS in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent ...